Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM)

Today's Latest Price: $18.58 USD

0.11 (0.60%)

Updated May 22 4:00pm

Add EPZM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

EPZM Stock Summary

  • EPZM's price/sales ratio is 108.77; that's higher than the P/S ratio of 97.62% of US stocks.
  • With a year-over-year growth in debt of 513.91%, Epizyme Inc's debt growth rate surpasses 96.38% of about US stocks.
  • As for revenue growth, note that EPZM's revenue has grown -41.66% over the past 12 months; that beats the revenue growth of only 4.48% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Epizyme Inc, a group of peers worth examining would be CAPR, MRUS, HTBX, ETON, and DCPH.
  • EPZM's SEC filings can be seen here. And to visit Epizyme Inc's official web site, go to www.epizyme.com.
EPZM Daily Price Range
EPZM 52-Week Price Range

EPZM Stock Price Chart More Charts


EPZM Price/Volume Stats

Current price $18.58 52-week high $27.82
Prev. close $18.47 52-week low $9.73
Day low $18.30 Volume 604,372
Day high $18.80 Avg. volume 1,000,414
50-day MA $16.95 Dividend yield N/A
200-day MA $16.87 Market Cap 1.88B

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about Epizyme Inc that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research | May 14, 2020

Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

Business Wire | May 13, 2020

Epizyme Reports Business Progress and First Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results. “The first quarter of 2020 was significant for Epizyme, marked by the FDA approval of TAZVERIK™ in eligible patients with epithelioid sarcoma and our transition to a commercial-stage company,” said Robert Bazemore, president and chief execut

Business Wire | May 4, 2020

Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 4, 2020

Epizyme Announces Date of First Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID

Business Wire | April 27, 2020

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo 2.77%
3-mo -13.54%
6-mo 11.73%
1-year 43.70%
3-year 19.10%
5-year -5.92%
YTD -24.47%
2019 299.35%
2018 -50.92%
2017 3.72%
2016 -24.47%
2015 -15.10%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9653 seconds.